Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cook TAA graft trial

This article was originally published in The Gray Sheet

Executive Summary

Firm completes enrollment for its STARZ-TX2 clinical trial comparing the Zenith TX2 endovascular graft to open surgery in the treatment of thoracic aortic aneurysms. The 200-patient trial, conducted at 39 sites, will evaluate patient survival and rupture rates over 12 months. WL Gore (Gore TAG) was first-to-market in the TAA endograft space in March 2005, with Medtronic (Talent) aiming to be next (1"The Gray Sheet" March 28, 2005, p. 13). Medtronic completed enrollment of its VALOR pivotal trial for Talent in June 2005...

You may also be interested in...

Medtronic’s Valiant thoracic aneurysm stent graft

Firm begins two clinical trials of its Valiant second-generation thoracic aortic aneurysm stent graft. Announced Dec. 15, the 125-patient Valor II U.S. trial will evaluate Valiant to treat descending thoracic aortic aneurysms. The firm also has initiated a 100-patient Virtue registry study in Europe to collect extra data on treatment of descending thoracic aortic dissections. Medtronic plans a U.S. marketing submission in two years. CE marked in 2005, Valiant is the leading thoracic aortic aneurysm endograft outside the United States, the firm says. Medtronic also offers its Talent thoracic stent graft outside the United States and hopes to gain FDA approval soon. Competitors include Cook (Zenith TX2) and Gore (TAG); the latter device is approved by FDA (1"The Gray Sheet" Aug. 7, 2006, In Brief)...

TAG Thoracic Endograft Approval Makes Gore First To Market In U.S.

Gore is negotiating with FDA the number of participants required for a post-approval study of TAG endoprosthesis to treat thoracic aortic aneurysms

Unilever Hit With Class Action Over Mercury-Laced Pond’s Cream Originating In Mexico

According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts